Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

2024-511030-12-00 Protocol CA127-1027 Human pharmacology (Phase I) - Other Ended

Start 3 Feb 2025 · End 20 Feb 2025 · Status Ended · 3 EU/EEA countries · 22 sites · Protocol CA127-1027

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 3
Sites 22

Non-small Cell Lung Cancer (NSCLC)

Key facts

Sponsor
Bristol-Myers Squibb Services Unlimited Company
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 Feb 2025 → 20 Feb 2025
Decision date (initial)
2024-11-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-511030-12-00
WHO UTN
U1111-1302-9694
ClinicalTrials.gov
NCT05828303

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-small Cell Lung Cancer (NSCLC)

VersionLevelCodeTermSystem organ class
27.0 PT 10059515 Non-small cell lung cancer metastatic 100000004864
21.1 PT 10029517 Non-small cell lung cancer stage I 100000004864
21.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bristol-Myers Squibb Services Unlimited Company

Sponsor organisation
Bristol-Myers Squibb Services Unlimited Company
Address
Plaza 254 Blanchardstown Corporate Park 2
City
Dublin 15
Postcode
D15 T867
Country
Ireland

Scientific contact point

Organisation
Bristol-Myers Squibb Services Unlimited Company
Contact name
GSM-CT

Public contact point

Organisation
Bristol-Myers Squibb Services Unlimited Company
Contact name
GSM-CT

Locations

3 EU/EEA countries · 22 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Not authorised 5 7
Italy Ended 3 4
Spain Ended 9 11
Rest of world
Australia, Brazil, United States
7

Investigational sites

France

7 sites · Not authorised
Institut De Cancerologie De L Ouest
Oncology, 15 Rue Andre Boquel, 49100, Angers
Centre Hospitalier Regional De Marseille
Oncology, 265 Chemin Des Bourrely, 13015, Marseille
Institut Bergonie
Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Hospitalier Universitaire De Poitiers
Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Centre Hospitalier Universitaire Grenoble Alpes
Oncology, Boulevard De La Chantourne, Cs 10217, Grenoble Cedex 9
Centre Hospitalier Universitaire De Nantes
Oncology, Boulevard Du Professeur Jacques Monod, 44800, Saint Herblain
Centre Hospitalier Universitaire De Rennes
Oncology, 2 Rue Henri Le Guilloux, 35000, Rennes

Italy

4 sites · Ended
Humanitas Mirasole S.p.A.
U.O. Di Oncologia ed Ematologia, Via Alessandro Manzoni 56, 20089, Rozzano
Ospedale Santa Maria Della Misericordia - Azienda Ospedaliera di Perugia
S.C. di Oncologia Medica, via Dottori 1, 06132, Perugia
Centro Ricerche Cliniche Di Verona S.r.l.
U.O.C. Oncologia, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Centro Di Riferimento Oncologico Di Aviano
S.O.C. Oncologia medica e dei tumori immuno-correlati, Via Franco Gallini 2, 33081, Aviano

Spain

11 sites · Ended
Hospital Hm Nou Delfos
Oncology, Avinguda De Vallcarca 151, 08023, Barcelona
Fundacion Instituto Valenciano De Oncologia
Oncology, Calle Professor Beltran Baguena 8, 46009, Valencia
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Clinica Universidad De Navarra
Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
MD Anderson Cancer Center
Oncology, Calle De Arturo Soria Nº 270, 28033, Madrid
Clinica Universidad De Navarra
Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Del Mar
Oncology, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Hospital Clinico San Carlos
Oncology, Calle Del Profesor Martín Lagos S/n, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-02-03

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-16 France Acceptable
2024-11-27
2024-11-27
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-17 Acceptable
2024-11-27
2024-12-17
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-12-19 Acceptable
2024-11-27
2024-12-19
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-01-29 France Acceptable
2024-11-27
2025-01-29